



BerGenBio

**Transitioning a strong scientific foundation
toward the market and significant value
generation**

www.bergenbio.com



Forward Looking Statements

Certain statements contained in this presentation constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and they can be identified by the use of forward-looking terminology, including the words "anticipate", "believe", "intend", "estimate", "expect", "will", "may", "should" and words of similar meaning. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Accordingly, no assurance is given that such forward-looking statements will prove to have been correct. They speak only as at the date of the presentation and no representation or warranty, expressed or implied, is made by BerGenBio ASA or its affiliates ("BerGenBio"), or by any of their respective members, directors, officers

or employees that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved and you are cautioned not to place any undue influence on any forward-looking statement. BerGenBio is making no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of this presentation, and neither BerGenBio nor any of its directors, officers or employees will have any liability to you or any other person resulting from the use of this presentation.

Copyright of all published material, including photographs, drawings and images in this presentation remain with BerGenBio and relevant third parties, as appropriate. Consequently, no reproduction in any form of the presentation, or parts thereof, is permitted without the prior written permission, and only with appropriate acknowledgements.



**Transitioning a strong
scientific foundation toward
the market and significant
value generation**

www.bergenbio.com

**BerGenBio is a world leader in exploring AXL
as a transformative treatment modality for
severe diseases**

**Lead program, bemcentinib, dosed in > 600
patients (~400 in oncology and ~200 in COVID)
and focus is now to advance bemcentinib in
two significant indications:**

- **1L STK11mutated NSCLC**
- **Hospitalized COVID-19 patients**


**A laser-focused plan and rightsizing the
organization for the two indications to unlock
clear value drivers within 18-24 months**

**BerGenBio retains all rights to its
candidates positioning it well for partnering**



Broad potential for bemcentinib, extensively explored with indications of clinical efficacy

Bemcentinib blocks AXL Activation in Multiple, Serious Diseases




Bemcentinib Phase II Studies

Patient Population	# of Patients Studied	Clinical Activity Observed
COVID-19	179	✓
AML	122	✓
NSCLC	78	✓
Melanoma	66	✓
MDS	45	✓
Mesothelioma	17	✓
Pancreatic cancer	9	
Glioblastoma	7	

A deep understanding of bemcentinib characteristics supports further clinical advancement

PRIMARY AREAS OF BEMCENTINIB ACCUMULATION



Brain – 26 fold*



Lungs – 48 fold*



POTENTIAL THERAPEUTIC IMPLICATIONS

- Bemcentinib crosses the blood brain barrier
- May be particularly important to treat metastases

- Relevant to both lung cancer and respiratory infections

BEMCENTINIB DOSING/PATIENT SELECTION


- Detailed analysis of target engagement, interaction with food conducted

POTENTIAL THERAPEUTIC IMPLICATIONS

- We will see sufficient blood levels to achieve efficacy in future studies
- Doses selected based on FDA “Project Optimus” providing improved therapeutic index and expected regulatory acceptability

Laser-focused strategy – priority on two unique opportunities to move bemcentinib towards the market

STRATEGIC ANALYSIS



CLINICAL FOCUS

1L STK11m NSCLC

- ✓ Compelling preclinical data
- ✓ Clinical activity in STK11m pts
- ✓ Proprietary position
- ✓ Few direct competitors
- ✓ Potential for early approval

COVID-19:

- ✓ Compelling preclinical data
- ✓ Clear efficacy from ACCORD2 data
- ✓ EUSolidAct study at minimal cost
- ✓ Potential for early approval
- ✓ Potential beyond COVID-19

OTHER POTENTIAL INDICATIONS

2L NSCLC

- **Evolution of 1L treatment;** no single 2L standard of care
- **Highly competitive;** 35,000 immunotherapy 2L trials on-going*

2L AML:

- **2L pts post-1L venetoclax;** poorly understood drivers of resistance
- **Additional clinical data needed** to support entry into pivotal

Tilvestamab


- **Early-stage** development
- **Additional data needed** to guide development path

Compelling rationale for 1L STK11m NSCLC

KEY DEVELOPMENT/COMMERCIALIZATION ADVANTAGES

- Significant patient population with limited response to Checkpoint inhibitors (CPIs)
- Bemcentinib restores activity of ICI's as demonstrated in preclinical studies and early clinical data
- Only selective AXL inhibitor in development for STK11m patients, along with a strong proprietary position
- FDA Fast Track status granted - STK11m predictor of poor outcome without specific therapeutic approaches today
- Potential for accelerated approval pathway

LARGE, UNSERVED PATIENT POPULATION




*Source: Global Data estimate in US, UK, Fr, Gr, Sp, It

**Per literature

STK11m NSCLC patients lack targeted therapies

1L Non-Squamous Non-Small Cell Lung Cancer




Multiple sources confirms that STK11m are associated with low response rates and shortened mOS with ICI treatment

~3% response rate with ICIs in STK11m pts

Immune Checkpoint Treatment	# of STK11 pts Responding/ # Treated
Nivolumab	0/11 ¹
Ipi-Nivo	0/7 ²
Durvalumab	1/21 ³
Durvalumab+ tremelimumab	1/23 ³


¹Skoulidis et al 2018 - ²Hellman et al 2018 - ³Kunkel et al 2018

Significantly shorter median overall survival



Skoulidis et al J Clin Oncol. 2019;37(15_suppl):102–102

Bemcentinib increases checkpoint inhibitor sensitivity in STK11m NSCLC





Bemcentinib has a novel MOA to generate new tumor specific CD8 T cells

- CD8+ T cells are key populations that respond to PD-1/L1 blockade
- Bemcentinib has a unique MOA that increases Type I interferon secretion from dendritic cells that drives the generation of **new** tumor-specific CD8 T cells, restoring therapeutic response to PD-1
- Within the field of immuno-oncology there is a focus to combine ICIs with agents that reinvigorate the immune response by reversing the exhaustion of CD8+T cells

2022 Cell Reports Medicine: compelling activity of bemcentinib in STK11m

THERAPEUTIC EFFECTS IN NSCLC XENOGRAFTS & PATIENTS



Data from on-going 2L NSCLC trial (BGBC008) indicates anti-tumor activity of bemcentinib in STK11m patients



Path forward in STK11 1L NSCLC



Key opinion leader interactions indicate high level of interest, awareness of STK11m and need for new therapeutics



STK11m NSCLC clinical program to initiate in H2 2022 with ph I/IIa study in the US, EU



Expansion of pre-clinical understanding including MoA and co-mutational efficacy




Strong rationale for hospitalized COVID-19

KEY DEVELOPMENT/COMMERCIALIZATION ADVANTAGES

- Despite recent approvals medical need in hospitalized patients persist
- Preclinical data indicate potential for broad variant coverage
- Profound efficacy signal seen in ACCORD2 study of hospitalized COVID-19 patients
- Accepted into the EUSolidAct platform study of an expected 500 hospitalized COVID-19 patients; expected to accrue rapidly
- Regulatory agencies are expected to continue to grant accelerated/emergency authorizations for promising drugs

COVID-19 HOSPITALIZATIONS CONTINUE

Number of COVID-19 patients in hospital




Source: Official data collated by Our World in Data – Last updated 29 April 2022

OurWorldInData.org/coronavirus • CC BY

Unmet needs persist and bemcentinib is likely to be effective against current and future viral variants

Bemcentinib provides broad COVID-19 variant inhibition



Adapted from: ECCMID 2022

New variants likely to occur

“The one thing we all have to be appreciative of is as long as there's virus circulating around the world there's the possibility and likelihood we're going to see more variants”



April 2022 Dr. Anthony Fauci, Head NIAID, NIH

Level of hospitalized patients stable

“At the end of week 15, 2022 ICU indicators remained stable over the last weeks but at a relatively high level, similar to the level observed in November 2021 ..”

17 April 2022 European Centre for Disease Prevention & Control

ACCORD2: bemcentinib met primary and key secondary endpoints with strong statistical significance



EUSolid Act: large number of sites, established capability to recruit into hospitalized COVID-19 study



- EUSolidAct has demonstrated the ability to rapidly recruit hospitalized COVID-19 patients
- Treatment with bemcentinib, or matched placebo, in addition to current SoC based on approved agents
- Study design reflects evolving nature of disease behavior due to effect of vaccines and variants
- Primary endpoint selected with consultation with EU and informed by data generated in two previous COVID-19 studies

Path forward in COVID-19




Demonstrable efficacy in patients on top of current SOC including remdesivir and corticosteroids

EUSolid Act provides opportunity to generate data in large, multi-site study in a highly cost-effective manner

COVID-19 data could lay foundation to explore bemcentinib in other severe infections, further expanding the market opportunity

Expedited regulatory authorizations continue to be issued and may provide a route to the market

Pipeline and future milestones of plan



19 S – Safety, E – Efficacy, IA – Interim Analysis, FPFV – First Patient First Visit, LPLV – Last Patient Last Visit, PoS – Proof of Signal (safety & efficacy), * Subject to Regulatory Agency endorsement, + Timelines assume no Dose Limiting Toxicity at each dose level



**Transitioning a strong
scientific foundation toward
the market and significant
value generation**

www.bergenbio.com

**BerGenBio is a world leader in exploring AXL
as a transformative treatment modality for
severe diseases**

**Lead program, bemcentinib, dosed in > 600
patients (~400 in oncology and ~200 in COVID)
- focus is now to advance bemcentinib in two
significant indications:**

- **1L STK11mutated NSCLC**
- **Hospitalized COVID-19 patients**

**A laser-focused plan and rightsizing the
organization for the two indications to unlock
clear value drivers within 18-24 months**

**BerGenBio retains all rights to its
candidates positioning it well for partnering**

